Close Menu

Prostate Cancer

News and reporting on prostate cancer.

Metastatic prostate cancer patients with BRCA, PALB2, FANCA, and CDK12 mutations had an improved response than those without such mutations, a study showed.

The team envisions developing an assay to guide targeted treatment for metastatic castration-resistant prostate cancer patients.   

A Phase II study suggests immune-related expression signatures and other immune markers may help find metastatic prostate cancer cases with better checkpoint blockade response.

Myriad has partnered with Japanese firm SRL, a subsidiary of Miraca Group, to commercialize its BRACAnalysis Diagnostic System in Japan.

The group now states that men with unfavorable intermediate-risk or high-risk disease can consider testing with Myriad's Prolaris or GenomeDx's Decipher.

The company has seen promising activity for the drug in KRAS-mutated metastatic colorectal cancer, and biomarker-defined patient subgroups with castration-resistant prostate cancer and AML.

The foundation-funded initiative from Jackson Laboratories has advanced a model for educating oncologists and providing access to tumor genomic profiling in the community setting.

The FDA granted priority review status to rucaparib for prostate cancer patients with BRCA1/2 mutations.

The LCD will provide coverage for the Decipher Prostate Biopsy genomic test for men with both favorable and unfavorable intermediate-risk prostate cancer. 

Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.

Pages